Microbot Medical INC 10-Q quarterly reports

Microbot Medical Inc. announced its Q2 2026 financial results, showing initial revenues from its LIBERTY Endovascular Robotic System following its full market release.

Microbot Medical reports Q1 2026 revenue of $105,000 as it transitions from development to commercialization of its LIBERTY Endovascular Robotic System.

Microbot Medical Inc. reports significant capital raises and FDA 510(k) clearance for its LIBERTY Endovascular Robotic Surgical System, enhancing its financial position and market readiness.

Microbot Medical reports significant capital raises and increased liquidity to fund ongoing research and development for its robotic surgical systems, despite widening net losses.

Microbot Medical Inc. announces its financial results for the first quarter of 2025, highlighting advancements in its LIBERTY Endovascular Robotic Surgical System and recent capital raising activities.

Microbot Medical Inc. announces its third quarter 2024 financial results, highlighting progress in its LIBERTY Endovascular Robotic Surgical System development and clinical trial.

Microbot Medical's Q2 2024 report highlights progress in clinical trials for its LIBERTY robotic system and details financial results including a net loss of $4.836 million for the first six months of 2024.

Microbot Medical reported its first quarter 2024 financial results, highlighting progress in its robotic surgery system development and ongoing financial challenges.